EP0546084A1 - Proteasen, die den abnormalen abbau von amyloid -g(b)-proteinvorläufern hervorrufen - Google Patents

Proteasen, die den abnormalen abbau von amyloid -g(b)-proteinvorläufern hervorrufen

Info

Publication number
EP0546084A1
EP0546084A1 EP91916872A EP91916872A EP0546084A1 EP 0546084 A1 EP0546084 A1 EP 0546084A1 EP 91916872 A EP91916872 A EP 91916872A EP 91916872 A EP91916872 A EP 91916872A EP 0546084 A1 EP0546084 A1 EP 0546084A1
Authority
EP
European Patent Office
Prior art keywords
protein
proteolytic
terminus
protease
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91916872A
Other languages
English (en)
French (fr)
Other versions
EP0546084A4 (en
Inventor
Carmela R. Abraham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of EP0546084A1 publication Critical patent/EP0546084A1/de
Publication of EP0546084A4 publication Critical patent/EP0546084A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
EP9191916872A 1990-08-17 1991-08-19 Proteases causing abnormal degradation of amyloid -g(b)-protein precursor Withdrawn EP0546084A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56880690A 1990-08-17 1990-08-17
US568806 1990-08-17

Publications (2)

Publication Number Publication Date
EP0546084A1 true EP0546084A1 (de) 1993-06-16
EP0546084A4 EP0546084A4 (en) 1994-10-19

Family

ID=24272818

Family Applications (1)

Application Number Title Priority Date Filing Date
EP9191916872A Withdrawn EP0546084A4 (en) 1990-08-17 1991-08-19 Proteases causing abnormal degradation of amyloid -g(b)-protein precursor

Country Status (5)

Country Link
EP (1) EP0546084A4 (de)
JP (1) JPH06503948A (de)
AU (1) AU643835B2 (de)
HU (1) HUT69771A (de)
WO (1) WO1992003542A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5338663A (en) * 1990-08-24 1994-08-16 President And Fellows Of Harvard College Method of identifying inhibitors of β-protein esterase activity
US5506097A (en) * 1990-08-24 1996-04-09 President And Fellows Of Harvard College Method for inhibiting β-protein enzymatic activity
US5292652A (en) * 1990-10-05 1994-03-08 Athena Neurosciences, Inc. Amyloidin protease and uses thereof
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines
JP3277211B2 (ja) * 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド アルツハイマー病の試験方法と治療方法
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
WO1994013319A1 (en) * 1992-12-16 1994-06-23 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
IL105793A0 (en) * 1992-05-28 1993-09-22 Lilly Co Eli Protease and related dna compounds
JP3466259B2 (ja) * 1993-04-27 2003-11-10 オリエンタル酵母工業株式会社 βＡＰ分解剤
US5679582A (en) * 1993-06-21 1997-10-21 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US6329163B1 (en) 1995-06-07 2001-12-11 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase inhibition
US5942400A (en) * 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
EP0791008A4 (de) 1995-09-08 2003-04-23 Anadys Pharmaceuticals Inc Screeningmethode für verbindungen, die eine affinität zur rns haben
CA2184195C (en) * 1995-10-25 2002-04-16 Andrew Pakula Screening method for identifying ligands for target proteins
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
EP0975796A4 (de) 1997-03-05 2004-04-21 Anadys Pharmaceuticals Inc Auswahlverfahren basierend auf anisotroper fluoreszenzzur indentifikation von verbindungen mit affinität zu nukleinsäuren
DK1030678T3 (da) 1997-11-12 2006-12-11 Johnson & Johnson Pharm Res Fremgangsmåde med höj kapacitet til funktionel klassificering af proteiner der identificeres under anvendelse af en genomikfremgangsmåde
HUP0104022A2 (hu) * 1998-06-05 2002-03-28 Aventis Pharma S.A. Béta-szekretáz típusú aktivitással rendelkező polipeptidek
FR2779444A1 (fr) * 1998-06-05 1999-12-10 Rhone Poulenc Rorer Sa Polypeptides possedant une activite de type beta-secretase et capables de cliver le precurseur naturel du peptide beta-amyloide (app)
US6569631B1 (en) 1998-11-12 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes
AR083819A1 (es) 2010-11-10 2013-03-27 Genentech Inc UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
CN107108745B (zh) 2014-11-19 2021-01-12 基因泰克公司 抗bace1的抗体和其用于神经疾病免疫疗法的用途
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J. NAVTIG ET AL 'Amyloid and Amyloidosis,1990; VIth International Symposium on Amyloidosis, Oslo, Norway, August 5-8, 1990' , KLUWER , DORDRECHT NL pages 718-721 C.ABRAHAM et al 'Proteolytic processing of beta-amyloid protein-related synthetic peptides and the beta-protein precursor by a protease purified from Alzheimer's disease brain' * the whole document * *
NEUROBIOLOGY OF AGING, vol.11, June 1990 page 303 C. ABRAHAM ET AL 'Studies on a brain protease thet cleaves at the N-terminus of beta-protein related synthetic peptides' *
NEUROBIOLOGY OF AGING, vol.11, June 1990 page 303 R. NELSON AND H. POTTER 'Purification of clipsin, an alpha1-antichymotrypsin-binding protease which cleaves the beta-protein precursor' *
See also references of WO9203542A1 *
T. MIYATAKE ET AL 'Molecular biology and genetics of Alzheimer's disease. Proceedings of the International Symposium on Dementia: Niigate, Japan, 11-14 November 1989' , EXCERPTA MEDICA , AMSTERDAM NL pages 159-166 C. ABRAHAM 'A Novel calcium-dependent protease from brain cleaves beta-protein-precursor-related synthetic peptides and is inhibited by alpha1-antichymotrypsin and protease nexin 2. * the whole document * *

Also Published As

Publication number Publication date
JPH06503948A (ja) 1994-05-12
AU643835B2 (en) 1993-11-25
EP0546084A4 (en) 1994-10-19
HU9300421D0 (en) 1993-11-29
HUT69771A (en) 1995-09-28
WO1992003542A1 (en) 1992-03-05
AU8538791A (en) 1992-03-17

Similar Documents

Publication Publication Date Title
US5200339A (en) Proteases causing abnormal degradation of amyloid β-protein precursor
EP0546084A1 (de) Proteasen, die den abnormalen abbau von amyloid -g(b)-proteinvorläufern hervorrufen
Roher et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.
Tacnet-Delorme et al. β-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for Aβ on the C1q globular regions
EP0527823A1 (de) Reinigung, nachweis und verfahren zur verwendung der protease-nexin-2
Gardella et al. Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA
Abraham et al. A calcium-activated protease from Alzheimer's disease brain cleaves at the N-terminus of the amyloid β-protein
EP0518955A1 (de) Chymotrypsinartige proteasen und ihre inhibitoren
JP2009100766A (ja) メマプシン２のインヒビターおよびその使用
US5213962A (en) Purification, detection and methods of use of protease Nexin-2
JPH05508919A (ja) スペクトリン又はその崩壊生成物の分析による細胞壊死検出
JPH10506015A (ja) Ｇｌｕｔ−４小胞に由来するインスリン−依存性の膜アミノペプチターゼのクローニング
David et al. Calpain II induced insolubilization of lens β-crystallin polypeptides may induce cataract
JPH09511332A (ja) カルパイン活性化を検出する方法およびカルパイン阻害剤を同定する方法
AU2002239727A1 (en) Inhibitors of memapsin 2 and use thereof
EP0546101A1 (de) Verfahren zur störung der bildung des alpha-antichymotrypsin-beta-protein-komplexe und synthetische peptide zur verwendung dabei
US4810780A (en) Protein having phospholipase A2 inhibitory activity
Wilson et al. Separation of ciliary dyskinesia substances found in serum and secreted by cystic fibrosis leukocytes and lymphoid cell lines, using protein A-Sepharose CL-4B
JP2000511408A (ja) 新規治療
JPS63246397A (ja) 起炎性フオスフオリパ−ゼａ▲下２▼阻害活性を有する蛋白
JPH06220088A (ja) アンジオテンシンｉ変換酵素を阻害するトリペプチドおよびその製造法ならびにそれを含む食品
JPH0427997B2 (de)
US3989821A (en) Polypeptides
JP2581823B2 (ja) ヒト炎症局所由来ホスホリパーゼａ▲下２▼阻害蛋白、その製造方法およびその遺伝子
JPH07227281A (ja) ペプチダーゼ及びその製造法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C12N 9/64

A4 Supplementary search report drawn up and despatched

Effective date: 19940902

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990302